Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.
about
Cervical Cytology Specimen Stability in Surepath Preservative and Analytical Sensitivity for HPV Testing with the cobas and Hybrid Capture 2 TestsHuman Papillomavirus Laboratory Testing: the Changing ParadigmCervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in DenmarkDiagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePath™ liquid-based pap specimensThe role of globular heads of the C1q receptor in HPV 16 E2-induced human cervical squamous carcinoma cell apoptosis is associated with p38 MAPK/JNK activation.Stability of cervical specimens in SurePath medium for human papillomavirus testing with the Roche cobas 4800 assay.Cervical cancer screening in Australia: Past and present.Negative HPV testing among patients with biopsy-proven cervical intraepithelial neoplasia grade 2/3 or cervical cancer.Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities.Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.RE: Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens.
P2860
Q35932079-578BFF83-05F1-465F-80AE-D7DC4F39805EQ36675236-146664F3-CFB4-4239-A1DB-FBF1A21A29E4Q36750670-6F54C432-78B4-4EDC-A646-AE20E8F9799BQ36753225-17C6FF87-27B5-41E9-A78A-2D49748C2AE7Q36837169-6442F338-6368-486A-9B15-6158AA792AADQ37264271-74D4D3BC-3265-48E3-8E60-DD07319EC2CBQ38619229-F58BC1DB-A1F3-44AF-9242-CD7A021207C2Q39014420-9A3BDE19-250B-4533-BA1E-03E8433D06D3Q39909954-D9CD76AC-6DE5-4A56-87E0-79E0DEFC8F3CQ40961076-A8D2D814-6B28-4DE1-A8FE-AB95B2E83F1CQ41247773-8D8DB5E6-5AE9-4AB4-90C2-5F9D6F2CBCE6Q41577992-F0BB56A9-0C70-413B-885D-517A65E80798Q41620477-AA142474-0E71-47D1-AD7C-94B15E26C52EQ48654742-BFF80D65-8E42-472D-A43D-372264AA5C3CQ55003928-119B2953-2E42-4E76-94B4-3D3FD9A8BB28
P2860
Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Limitations of widely used hig ...... in cervical cancer screening.
@ast
Limitations of widely used hig ...... in cervical cancer screening.
@en
type
label
Limitations of widely used hig ...... in cervical cancer screening.
@ast
Limitations of widely used hig ...... in cervical cancer screening.
@en
prefLabel
Limitations of widely used hig ...... in cervical cancer screening.
@ast
Limitations of widely used hig ...... in cervical cancer screening.
@en
P2860
P356
P1476
Limitations of widely used hig ...... in cervical cancer screening.
@en
P2093
R Marshall Austin
Sonya Naryshkin
P2860
P304
P356
10.2147/DHPS.S37273
P407
P577
2012-11-02T00:00:00Z